{"entity":{"id":"nct07314723","kind":"trial","name":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","aka":[],"tldr":"A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","summary":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer is a phase 2 interventional study registered as NCT07314723 by Mabwell (Shanghai) Bioscience Co., Ltd., with 90 participants planned, started 2025-08-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: 9MW2821 and Toripalimab Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07314723","url":"https://clinicaltrials.gov/study/NCT07314723"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07314723","phase":"2","setting":"A Single Arm, Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety and Efficacy of 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","enrolled":90,"outcomes":[]},"route":"/trials/nct07314723/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}]}}